81 related articles for article (PubMed ID: 21418965)
21. O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
Passagne I; Evrard A; Depeille P; Cuq P; Cupissol D; Vian L
Toxicol Appl Pharmacol; 2006 Mar; 211(2):97-105. PubMed ID: 16039682
[TBL] [Abstract][Full Text] [Related]
22. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
23. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
24. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
[TBL] [Abstract][Full Text] [Related]
25. [MGMT analysis in gliomas].
Quillien V; Vauléon E; Saikali S; Lesimple T; Hamlat A; Etcheverry A; Mosser J
Bull Cancer; 2011 Mar; 98(3):291-303. PubMed ID: 21459716
[TBL] [Abstract][Full Text] [Related]
26. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
28. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
30. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Pollack IF; Hamilton RL; Sobol RW; Nikiforova MN; Nikiforov YE; Lyons-Weiler MA; LaFramboise WA; Burger PC; Brat DJ; Rosenblum MK; Gilles FH; Yates AJ; Zhou T; Cohen KJ; Finlay JL; Jakacki RI;
Pediatr Blood Cancer; 2010 Dec; 55(6):1066-71. PubMed ID: 20589656
[TBL] [Abstract][Full Text] [Related]
31. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
32. Quantitation of ERCC-2 gene expression in human tumor cell lines by reverse transcription-polymerase chain reaction in comparison to northern blot analysis.
Chen ZP; Malapetsa A; Mohr G; Brien S; Panasci LC
Anal Biochem; 1997 Jan; 244(1):50-4. PubMed ID: 9025907
[TBL] [Abstract][Full Text] [Related]
33. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
34. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
[TBL] [Abstract][Full Text] [Related]
35. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
36. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
37. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds.
Tanaka S; Kobayashi I; Utsuki S; Oka H; Yasui Y; Fujii K
Oncol Rep; 2005 Nov; 14(5):1275-80. PubMed ID: 16211296
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R
Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944
[TBL] [Abstract][Full Text] [Related]
40. [Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Molnár P; Méhes G
Magy Onkol; 2009 Mar; 53(1):33-8. PubMed ID: 19318324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
